Alzheimer’s Therapy Elenbecestat Reduces Brain Amyloid Levels, is Safe and Well-Tolerated, Trial Shows

Alzheimer’s Therapy Elenbecestat Reduces Brain Amyloid Levels, is Safe and Well-Tolerated, Trial Shows
Treatment with the investigational compound elenbecestat reduced brain amyloid beta levels and was safe and well-tolerated, according to Phase 2 clinical trial results. The presence of amyloid beta plaques is a major characteristic of the brains of Alzheimer’s disease patients. Amyloid beta is produced through the work of a key enzyme called BACE (beta-amyloid cleaving enzyme). Elenbecestat is

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Jim Deitrick says:

    My wife is 71 and is in the moderate to final stages of AD. Under the newly passed Right To Try Law is this something that she can ask for?

Leave a Comment

Your email address will not be published. Required fields are marked *